IT WAS A MIXED BAG OF THIRD QUARTER FINANCIAL RESULTS for the nation’s largest in vitro diagnostics (IVD) manufacturers, with COVID-19 testing volume a contributing factor. Fluctuating demand for SARS-CoV-2 testing proved perplexing, as some IVD companies saw an increase in sales of these tests, while some IVD firms reported a nosedive in related test […]
Top Public IVD Companies Report Q3/Q4 2022 Earnings
Many firms looking beyond SARS-CoV-2, with testing demand generally dropping year over year
- By Robert Michel
- > From the Volume XXIX, No. 17 - December 12, 2022 Issue
- Tags: Abbott Laboratories, advanced staining, Andrew Last, BD, Beckman Coulter, Becton Dickenson and Company, Bernd Montag PhD, Bio-Rad Laboratories, bioMerieux, Bond-Prime, Cepheid, Christopher DelOrefice, cobas 6800, cobas 8000, COVID-19 antigen test, COVID-19 rapid test, Danaher, Elecsys amyloid plasma panel, FDA, Hologic, immunoassay, in vitro diagnostics, IVD, ivd/lab informatics, leica biosystems, life sciences, Marc Casper, molecular biology, molecular diagnostics, New Mountain Capital, Norman Schwartz, PCR molecular test, PCR-based nucleic acid test, PerkinElmer, Prahlad Singh, QuidelOrtho, Rainer Blair, Respiratory syncytial virus, Robert Ford, Roche, roche diagnostics, RSV, SARS-CoV-2 test, Severin Schwan, Siemens Healthineers, Stephen McMillan, sysmex, Thermo Fisher Scientific, Thomas Polen, Thomas Schinecker PhD, US Food and Drug Administration, Wall Street Journal
